We are live on ! Find out more
CLCD

CoLucid Pharmaceuticals, Inc.
CLCD

Delisted

CLCD was delisted on the 28th of February, 2017.

Back to rankings

56 hedge funds and large institutions have $472M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

925% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 4

921% more capital invested

Capital invested by funds: $46.3M → $472M (+$426M)

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

180% more funds holding

Funds holding: 20 → 56 (+36)

Holders
56
Holders Change
+36
Holders Change %
+180%
% of All Funds
1.49%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.16%
New
41
Increased
10
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.1M
2
BI
BVF Inc
California
+$11.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.6M
4
PA
Perceptive Advisors
New York
+$8.16M
5
GPP
Great Point Partners
Connecticut
+$5.91M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.48M
2
EAM
EverPoint Asset Management
Connecticut
-$650K
3
SG Americas Securities
SG Americas Securities
New York
-$464K
4
UOC
UBS O'Connor
Illinois
-$368K
5
MAM
MPM Asset Management
Massachusetts
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Atika Capital Management
New York
$2.86M +$1.11M +75,000 New
BCM
27
Bridgeway Capital Management
Texas
$2.67M +$296K +20,000 +40%
VM
28
VHCP Management
New York
$2.6M +$1.01M +68,190 New
EA
29
Emerald Acquisition
Washington
$2.22M +$862K +58,296 New
Ameriprise
30
Ameriprise
Minnesota
$2.17M +$843K +57,011 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$2.15M +$376K +25,456 +82%
AG
32
Artal Group
Luxembourg
$2.12M +$739K +50,000 +897%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$1.86M +$338K +22,834 +88%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.44M +$557K +37,686 New
PPA
35
Parametric Portfolio Associates
Washington
$1.44M +$556K +37,612 New
WMSA
36
Weiss Multi-Strategy Advisers
New York
$1.22M +$473K +32,000 New
BBA
37
Baker Bros. Advisors
New York
$1.16M +$448K +30,310 New
Millennium Management
38
Millennium Management
New York
$997K +$386K +26,135 New
DC
39
Deere & Company
Illinois
$624K +$242K +16,366 New
Morgan Stanley
40
Morgan Stanley
New York
$486K +$181K +12,237 +2,447%
Neuberger Berman Group
41
Neuberger Berman Group
New York
$458K +$177K +12,000 New
VKH
42
Virtu KCG Holdings
New York
$453K +$175K +11,870 New
EMG
43
Ellington Management Group
Connecticut
$439K +$170K +11,500 New
Northern Trust
44
Northern Trust
Illinois
$421K +$163K +11,047 New
MIM
45
Monashee Investment Management
Massachusetts
$420K – – –
KCM
46
Kornitzer Capital Management
Kansas
$381K +$148K +10,000 New
TC
47
TFS Capital
Pennsylvania
$375K +$145K +9,831 New
RJA
48
Raymond James & Associates
Florida
$343K +$133K +9,000 New
BFA
49
BlackRock Fund Advisors
California
$327K +$1K +68 +0.8%
Jane Street
50
Jane Street
New York
$203K +$78.8K +5,332 New
1
2
3

CLCD Hedge Fund Activity: Q3 2016 in Review

56 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q3 2016, worth a combined $472M — up 921% from $46.3M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new CLCD positions and 4 closed out — a net gain of 37 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $17.1M. The largest seller was Sphera Funds Management, cutting an estimated $1.48M.

  • 56 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q3 2016, up from 20 in Q2 2016.
  • Funds reported $472M of CoLucid Pharmaceuticals, Inc. stock for Q3 2016, up 921% quarter-over-quarter.
  • 41 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q3 2016 and 4 closed out, a net change of +37 holders.
  • The largest CoLucid Pharmaceuticals, Inc. buyer in Q3 2016 was T. Rowe Price Associates, an estimated $17.1M added.
  • The largest CoLucid Pharmaceuticals, Inc. seller in Q3 2016 was Sphera Funds Management, an estimated $1.48M sold.

Based on aggregated 13F filings for Q3 2016.